

MIDAZOLAM

PRESENTATION:

Ampoules containing 10mg in 2ml of midazolam (5mg/ml)
Ampoules containing 10mg in 5ml of midazolam (2mg/ml)
Ampoules containing 50mg in 10ml of midazolam (5mg/ml)

Prefilled syringe containing 50mg in 50mL of midazolam (1mg/ml)

INDICATION:

Sedation
Treatment of status epilepticus

DOSE AND ADMINISTRATION:

ICU STANDARD INFUSION

Single strength

Preparation available	Amount to be diluted with glucose 5%	Final volume	Final concentration
10mg in 2ml	60mg (12ml)	60ml	1mg/ml
10mg in 5ml	60mg (30ml)	60ml	1mg/ml
50mg in 10ml	50mg(10ml)	50ml*	1mg/ml
50mg in 50ml PFS	No dilution required		

Double strength

Preparation available	Amount to be diluted with glucose 5%	Final Volume	Final concentration
10mg in 2ml	120mg (24ml)	60ml	2mg/ml
10mg in 5ml	120mg (60ml)	60ml	2mg/ml
50mg in 10ml	100mg(20ml)	50ml*	2mg/ml
50mg in 50ml PFS	Not suitable		

**note when using preparations with a final volume of 50ml these will not be compatible with the drug library (DERS)*

Sedation: Initially 2-5mg/hour titrated to the required level.
BNF recommended dose of 0.03-0.2mg/kg/hr

Status epilepticus: Maintenance infusion 0.05-0.4mg/kg/hr.
i.e. for 70kg patient 3.5- 28mg/hr.
Use double strength midazolam.

Critical Care Guidelines: MIDAZOLAM SOLUTION FOR INJECTION	
Authors: Fiona Clarke, Updated by Laura Kirkpatrick	
Document Version: 4	Authoriser: Lothian Critical Care Directorate QIT Editorial Board
Authorisation Date: March 2023	Review Date: March 2025

Bolus doses

Sedation bolus doses of 500micrograms to 2 mg may be given. Bolus doses are generally given via the infusion pump. If the patient is not prescribed a continuous infusion prepare as below:

Preparation available	Amount to be diluted with glucose 5%	Final Volume	Final concentration
10mg in 2ml	10mg (2ml)	10ml	1mg/ml
10mg in 5ml	10mg (5ml)	10ml	1mg/ml
50mg in 10ml	10mg(2ml)	10ml	1mg/ml

Using the 10mg/2ml or 10mg/5ml preparation for bolus doses is preferred to prevent wastage but the 50mg/10ml preparation may be used if there are supply issues with the 10mg/2ml or 10mg/5ml preparation.

CONCENTRATION: **Single strength** :1mg/ml
 Double strength:2mg/ml

STABILITY: Physically and chemically stable for 24 hours at room temperature.
 Also stable in sodium chloride 0.9%.
 Prefilled syringe should not be mixed with any other medicinal products

References:

1. Summary of Product Characteristics, Midazolam 5mg/ml solution for injection/infusion, .Hameln pharmaceuticals ltd, www.medicines.org.uk/emc/product/6420/smpc last reviewed 06/03/2023.
2. Injectable Medicines Guide accessed online at www.injguide.nhs.uk on 06/03/2023.
3. NHS Lothian Critical Care Guideline of Treatment of status epilepticus, reviewed March 2023.
4. Summary of Product Characteristics, Midazolam 1mg/ml solution for injection/infusion in a prefilled syringe, Ranbaxy UK, <https://www.medicines.org.uk/emc/product/10967/smpc> last reviewed 06/03/2023

Critical Care Guidelines: MIDAZOLAM SOLUTION FOR INJECTION	
Authors: Fiona Clarke, Updated by Laura Kirkpatrick	
Document Version: 4	Authoriser: Lothian Critical Care Directorate QIT Editorial Board
Authorisation Date: March 2023	Review Date: March 2025